跳至主要内容
临床试验/NCT04510961
NCT04510961已完成不适用

Beneficial Effects of Paraffin Bath Therapy as Additional Treatment of Chronic Hand Eczema: A Randomized Controlled Trial

Cairo University2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年1月10日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
SCORAD ("SCORing Atopic Dermatitis

研究概览

简要总结

Objective: Chronic Hand eczema (CHE) is a common inflammatory skin disease has a major medical psychological and socio-economic implications that affect quality of life (QoL)and work ability. This study, the first randomized controlled trial that will be conducted to evaluate the effect of paraffin bath therapy (PBT) in the treatment of CHE.

详细描述

Design: The study design is a randomized controlled trial with measures at pre-and post-intervention.

Subjects: Sixty patients with moderate to severe Chronic Hand eczema (CHE) will participate in the study. They will be classified randomly into two groups of equal number; paraffin group and the control group.

Interventions: Paraffin group will receive Paraffin bath therapy for 5 days per week for 12 weeks in addition to routine skin care program while the control group will receive routine skin care program.

Outcome Measures:

Objective SCORing Atopic Dermatitis, subjective item score and dermatology life quality index (DLQI) will be assessed before, at 6th week and at 12th week of treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

Measurements will be at three occasions: at randomization (T1), at 6th week (T2) and at 12th week (T3) of treatment. Evaluative procedures will be by a blind assessor

入排标准

年龄范围
20 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age from 20-40 years
  • Time elapsed from the beginning of the disease ; more than three months according to the Guideline of the German Dermatological Society

排除标准

  • active eczematous lesions on other parts of the body;
  • malignant or premalignant skin tumors

结局指标

主要结局

SCORAD ("SCORing Atopic Dermatitis

时间窗: Change from Baseline at SCORAD score at 6th week and at 12th weeks of treatment

is the most widely clinical tool for assessing the severity (i.e. extent, intensity) of atopic dermatitis as objectively as possible.20 It consists of six objective items (erythema, oedema/papules, effect of scratching, oozing/crust formation, lichenification, and dryness), and two subjective symptoms (itch and sleeplessness), the maximum score is 103 points

次要结局

  • Dermatology life quality index (DLQI)(Change from Baseline at 6th week and at 12th weeks of treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

ZIZI MOHAMMED IBRAHIM ALI

ASSOCIATE PROF

Cairo University

研究点 (2)

Loading locations...

相似试验